Among 400 primary prevention patients in a community cardiology practice, coronary artery calcium (CAC) score tracked tightly with management changes. Lipid therapy modification rose from 7.7% at CAC 0 to 81.7% at CAC ≥400; aspirin initiation among aspirin-naive patients rose from 1.0% to 52.5%; stress testing from 2.7% to 68.6%. Each one-category CAC increase carried an adjusted odds ratio of roughly 4 to 5 for each action. CAC shifted MESA risk category in 55.2% of patients, 87 upward and 105 downward.
The pattern is what guidelines intend: a zero score lets patients and clinicians defer or skip statins, while a high score pushes toward treatment. The downward reclassification of 105 patients matters as much as the upward shifts, since it identifies people who may safely avoid medication. Two cautions apply. First, the design cannot show that these decisions improved outcomes; the authors say so explicitly, and this is a single-practice, six-month retrospective look at prescribing behaviour. Second, the aspirin result deserves scrutiny. Roughly half of aspirin-naive patients with CAC ≥100 started it, yet recent primary prevention trials show bleeding risk offsetting benefit in most adults, and guidelines reserve aspirin for carefully selected cases. Starting aspirin on calcium alone may overreach the evidence, and the 68.6% stress testing rate at CAC ≥400 may reflect downstream cascade effects. Editorially, this is confirmatory: it shows CAC changes clinician behaviour in routine practice, not that behaviour change helps patients. Adults considering a CAC scan should discuss beforehand what a result would change.